Equities

Stevanato Group SpA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Stevanato Group SpA

Actions
Health CareMedical Equipment and Services
  • Price (USD)15.60
  • Today's Change0.37 / 2.43%
  • Shares traded488.00k
  • 1 Year change-21.84%
  • Beta0.5739
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

  • Revenue in USD (TTM)1.39bn
  • Net income in USD166.89m
  • Incorporated1949
  • Employees5.52k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DENTSPLY SIRONA Inc3.62bn-882.00m2.74bn14.00k--1.85--0.7549-4.43-4.4318.187.410.59032.725.47258,857.10-14.35-4.06-18.88-4.8351.1053.14-24.31-8.590.98659.680.6184---4.34-1.17-589.39--7.9111.28
Integer Holdings Corp1.83bn87.20m3.05bn11.00k36.371.7514.461.672.402.3951.7649.830.55785.044.83166,461.302.663.282.843.5427.1526.704.766.382.455.230.41120.0010.356.4135.805.8216.99--
LivaNova PLC1.35bn-217.49m3.63bn2.90k--3.13--2.69-4.01-4.0124.6421.190.53112.586.60465,159.30-8.56-4.14-11.07-5.0368.5067.61-16.12-9.041.1210.220.273--8.662.94260.39--10.98--
ICU Medical Inc2.32bn-7.36m3.65bn15.00k--1.7118.611.57-0.3109-0.310994.3086.170.5522.2412.70154,690.90-0.206-0.2042-0.2351-0.230636.4733.82-0.3731-0.33261.191.620.3829--5.4413.47-296.86---3.18--
Lantheus Holdings Inc1.53bn167.68m4.46bn808.0028.263.9919.212.922.382.3821.9016.880.70558.674.481,888,531.007.759.8710.5011.3362.2360.4410.9912.862.49--0.3370.0018.3234.59-4.3558.0629.27--
TransMedics Group Inc566.35m90.47m4.56bn728.0056.0012.8139.248.042.382.4114.4810.400.65414.656.63777,958.8010.45-5.7311.37-6.2860.2862.3715.97-11.867.1331.190.5903--82.7479.64241.70--279.42--
Stevanato Group SpA1.39bn166.89m4.72bn5.52k25.512.5017.753.400.61140.61145.096.250.50582.952.65251,631.706.088.027.6310.9429.2731.0112.0113.241.3030.000.23866.821.7215.53-19.1324.6133.52--
Teleflex Inc3.19bn-327.85m4.73bn14.10k--1.24--1.48-7.35-7.3670.5586.480.41542.056.00226,240.30-4.274.58-4.695.0153.6754.77-10.2811.381.536.780.411419.742.453.26-80.38-31.404.250.00
Merit Medical Systems Inc1.48bn118.43m4.82bn7.40k41.613.1519.703.261.951.9524.3725.800.58982.397.38199,611.904.733.495.173.9348.4745.378.025.652.8614.410.3240.007.896.4027.4885.69-14.13--
iRhythm Holdings, Inc702.57m-51.46m4.90bn2.00k--40.19--6.98-1.62-1.6222.113.780.737712.049.15351,286.50-5.40-20.12-6.21-24.3770.3568.61-7.32-23.904.50--0.8418--20.1322.508.20--19.06--
Envista Holdings Corp2.72bn47.00m4.96bn12.30k110.101.6030.411.820.27490.274916.1018.960.49314.636.86--0.8523-2.141.01-2.5854.9356.631.73-5.212.046.730.318--8.327.11104.202.03-1.03--
Caris Life Sciences Inc-100.00bn-100.00bn6.07bn----12.68----------1.70------------------------9.36--0.4404--34.67--18.22------
Glaukos Corp469.82m-87.61m6.26bn995.00--8.13--13.33-1.55-1.558.2813.410.48791.766.06472,180.90-9.10-11.24-9.92-12.0476.8773.54-18.65-36.684.47--0.0817--21.8510.10-8.70--5.93--
Bruker Corp3.44bn-23.70m6.45bn11.40k--2.6433.441.87-0.1562-0.156222.6516.060.54811.445.23301,763.80-0.35546.80-0.45239.2048.0050.00-0.64859.660.88779.340.446210.8713.5610.19-73.53-10.529.574.56
Avantor Inc6.58bn-82.20m6.57bn13.50k--1.1820.190.9996-0.1203-0.12039.648.170.53645.586.07487,051.80-0.67063.94-0.76934.4833.1333.76-1.256.870.96393.950.40920.00-2.642.35121.58--23.59--
Data as of Feb 11 2026. Currency figures normalised to Stevanato Group SpA's reporting currency: US Dollar USD

Institutional shareholders

62.94%Per cent of shares held by top holders
HolderShares% Held
Conestoga Capital Advisors LLCas of 31 Dec 20257.89m15.91%
Neuberger Berman Investment Advisers LLCas of 30 Nov 20254.96m10.00%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20253.55m7.17%
TimesSquare Capital Management LLCas of 31 Dec 20253.50m7.06%
Thrivent Asset Management LLCas of 31 Dec 20252.36m4.75%
Artisan Partners LPas of 31 Dec 20252.35m4.74%
BAMCO, Inc.as of 30 Sep 20251.97m3.98%
Jennison Associates LLCas of 31 Dec 20251.77m3.57%
Silvercross Investment Management BVas of 31 Jul 20251.47m2.96%
ArrowMark Colorado Holdings LLCas of 30 Sep 20251.39m2.81%
More ▼
Data from 31 Jul 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.